shortagewatch

Home / Companies / Servier

Company family · HQ FR

Servier: medicine shortages

private (foundation)

As of 2 Nov 2026, 9 Servier products have a reported shortage across 6 countries, covering 7 medicines.

Products short9rank #194 of 464
Medicines7active ingredients
Countries6/16
New in 90 days4+2 vs market pace
Typical duration5 monthsmedian so far
Manufacturing33%demand-driven 56%

Where

Canada1Germany1Italy1Austria3Belgium1Norway2

Which therapeutic classes

Cardiovascular system5Cancer and immune system2Various1Digestive tract and metabolism1

Why, compared with all companies

Manufacturing problemIncreased demandActive ingredient shortageDistribution or logisticsCommercial decision or withdrawalRegulatory or licensingOtherNot stated
ServierServier: Manufacturing problem 3 (38%)38%Servier: Increased demand 5 (62%)62%All companiesAll companies: Manufacturing problem 4,893 (36%)36%All companies: Increased demand 1,873 (14%)14%All companies: Active ingredient shortage 367 (3%)All companies: Distribution or logistics 336 (2%)All companies: Commercial decision or withdrawal 435 (3%)All companies: Regulatory or licensing 131 (1%)All companies: Other 1,244 (9%)9%All companies: Not stated 4,221 (31%)31%

Manufacturing problems point to the company's own supply chain; increased demand often follows a competitor's shortage or a demand shock.

Latest changes

All changes

No changes recorded yet. Changes are tracked from our daily snapshots.

Open shortages over time

566731 Oct2026-10-31: 61 Nov2026-11-01: 62 Nov2026-11-02: 6

Products short per day in the 5 countries tracked since 31 Oct 2026, from our daily snapshots. The history lengthens every day.

When its current shortages began

00112Dec: 0Jan ’25: 0Feb: 0FebMar: 0Apr: 0May: 0MayJun: 0Jul: 0Aug: 0AugSep: 2Oct: 0Nov: 1NovDec: 0Jan ’26: 0Feb: 0FebMar: 0Apr: 0May: 0MayJun: 1Jul: 0Aug: 1AugSep: 0Oct: 2Nov: 1Nov

Long-run trend in Canada

Canada dashboard
051015202018: 320182019: 1020192020: 920202021: 320212022: 620222023: 1720232024: 1520242025: 720252026: 102026

Canada publishes every report since 2017, so it shows whether this company is reporting more or fewer shortages over time. The current year is partial.

Against its peers

Viatris995Teva903Sandoz599Pfizer491Accord (Intas)484Stada349Zentiva340Fresenius Kabi339Apotex326Sun Pharma250Aurobindo226Towa (Pensa)201Krka187Sanofi158Servier9

Breadth vs depth

1101001,00010,0001101001,000Products short (log scale)Medicines affected (log scale)Viatris: 995 / 248ViatrisTeva: 903 / 289TevaSandoz: 599 / 198SandozPfizer: 491 / 122PfizerAccord (Intas): 484 / 151Accord (Intas)Stada: 349 / 140Zentiva: 340 / 159ZentivaFresenius Kabi: 339 / 81Apotex: 326 / 152Sun Pharma: 250 / 77Aurobindo: 226 / 111Towa (Pensa): 201 / 102Krka: 187 / 67Sanofi: 158 / 45Jamp: 151 / 74Baxter: 149 / 27Sawai: 148 / 68Hikma: 126 / 44Glenmark: 105 / 39Sanis: 98 / 54Cheplapharm: 86 / 28GSK: 85 / 38Advanz (Amdipharm): 81 / 24Nichi-Iko: 77 / 29Takeda: 76 / 10Johnson & Johnson: 75 / 19Neuraxpharm: 75 / 19Novartis: 70 / 32Bayer: 68 / 17Biomed: 64 / 21Daiichi Sankyo: 59 / 18Orifarm: 59 / 40Medochemie: 56 / 14Pharmascience: 51 / 32Marcan: 51 / 16Doc Generici: 50 / 25B. Braun: 49 / 17AA Pharma: 46 / 26H E: 46 / 15Octapharma: 42 / 6Jv E: 42 / 1Kyowa Pharmaceutical: 42 / 16Novo Nordisk: 41 / 8Odan: 41 / 31Aspen: 41 / 13Sterop: 41 / 16Nipro: 41 / 17Dr. Reddy's: 40 / 24Organon: 40 / 20Laboratoire Riva: 40 / 23Kern Pharma: 40 / 30Bausch Health: 39 / 30Bracco: 38 / 6G.L.: 38 / 13Tatsumi Kagaku: 38 / 24Otsuka: 37 / 4Eli Lilly: 37 / 12Piramal Critical: 35 / 13Imuna Pharm: 35 / 4AbbVie: 34 / 15Medical Valley: 34 / 8Orion: 34 / 24Rowex: 34 / 19Takata Pharmaceutical: 33 / 17Aristo: 32 / 16Norgine: 32 / 3Gedeon Richter: 31 / 11Eql: 31 / 9Guerbet: 30 / 5Lukas Heil-Betriebsst: 30 / 0Roche: 29 / 14Omega: 29 / 18Bgp: 29 / 18Holsten -: 29 / 3Menarini: 29 / 17Paladin: 28 / 17Grifols: 28 / 9Ge: 28 / 6Merck & Co. (MSD): 27 / 14Ferring: 27 / 7Servier: 9 / 7Servier

Further right: more products short. Higher: more different medicines affected.

Medicines short

Download CSV
MedicineWhere this company is shortProductsEarliest startMain reasonShort anywhere
Perindopril and Diuretics223 Oct 2026Increased demand6/16
Trifluridine, Combinations22 Sep 2025Increased demand1/16
Gliclazide111 Jun 2026Increased demand8/16
Ibritumomab Tiuxetan (90Y)11 Dec 2020Manufacturing problem2/16
Ivabradine14 Nov 2025Increased demand9/16
Perindopril131 Aug 2026Quality problem or recall5/16
Perindopril and Amlodipine128 Oct 2026Manufacturing problem5/16

Shortage data describes supply, not company finances. A shortage can mean lost sales for the supplier or extra demand for its competitors. Nothing here is investment advice; tickers are for identification only and may be out of date.